Fiocruz Completes National Production of Dolutegravir, Bolstering Brazil's HIV Treatment Autonomy
Fiocruz completes technology transfer enabling Brazil to produce dolutegravir locally, securing HIV treatment access for over 770,000 patients.
- • Fiocruz completed the technology transfer for national production of dolutegravir, a key HIV medication.
- • Over 770,000 Brazilians living with HIV use dolutegravir, freely provided by the public health system.
- • National production reduces reliance on international suppliers and strengthens supply security.
- • The partnership with ViiV Healthcare and GSK was crucial to enable local manufacturing.
Key details
The Oswaldo Cruz Foundation (Fiocruz) has successfully finalized the technology transfer enabling the national production of dolutegravir, Brazil's primary antiretroviral drug used to treat HIV. This milestone allows Brazil, through its Pharmaceutical Technology Institute (Farmanguinhos), to oversee all manufacturing stages, enhancing the Unified Health System's (SUS) autonomy and ensuring equitable access to this vital medication.
Currently, over 770,000 people living with HIV in Brazil rely on dolutegravir, which the public health system provides free of charge. By nationalizing production, Brazil reduces dependence on international suppliers and strengthens supply security, mitigating risks from global market fluctuations or supply chain disruptions.
The technology transfer was conducted in partnership with ViiV Healthcare, a GSK subsidiary and the original developer of dolutegravir. This collaboration involved a comprehensive process of industrial adaptation, training, and knowledge absorption necessary for Farmanguinhos to manufacture the drug at required standards. Fiocruz highlighted the collaboration as a model that reinforces Brazil's scientific and industrial capacity for producing essential medicines.
This development not only solidifies Brazil’s position in HIV treatment provision but also represents a broader strategic effort to expand national production capabilities of critical medications, bolstering public health infrastructure. The move is expected to strengthen Brazil’s sovereignty over pharmaceutical production and support the accessibility of effective HIV therapies within the country.
This article was translated and synthesized from Brazilian sources, providing English-speaking readers with local perspectives.
